Thanks, I agree. When you think for a second about these two populations... rGBM and platinum(and mostly avastin resistant) ovarian cancers.... you are talking about folks at the absolute end of the line with expected life expectancies measured in months. I'm much more bullish about VB-111 since it is producing compelling results in such difficult to treat populations.
Yes, fast tract and orphan drug status given the small population. How about breakthrough designation ? VBLT cold certainly apply for BDT based on the ovarian cancer results.
News 
Market Data 
Discover 
